Amgen Defends Tavneos as FDA Renews Withdrawal Push Over Data Manipulation Claims

Pharmaceutical company Amgen is actively defending its rare disease medication, Tavneos, as the U.S. Food and Drug Administration again requests its removal from the market. The FDA cites new evidence suggesting data manipulation in the drug's key study, which reportedly exaggerated its effectiveness. This follows the retraction of the pivotal study's paper by a major medical journal last month. Amgen, which acquired the drug's original developer, maintains its confidence in Tavneos and plans to provide updated study results to the FDA later this month.